WCN25-2671 DEVELOPMENT AND EVALUATION OF CLINICAL RISK PREDICTION MODELS USING BONE TURNOVER MARKER FOR OSTEOPOROSIS SCREENING IN CHRONIC HEMODIALYSIS PATIENTS

Conclusions: This real-world study suggests that Desidustat is a safe and effective alternative to erythropoietin for managing anemia in CKD patients providing similar efficasy.The oral route of Desidustat increases patient convenience.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.